May 22, 2018 5:07 AM ET

Pharmaceuticals

Company Overview of QuVa Pharma, Inc.

Company Overview

QuVa Pharma, Inc. manufactures and markets pharmaceutical compounds. The company is based in Sugar Land, Texas.

1075 West Park One Drive

Suite 100

Sugar Land, TX 77478

United States

Key Executives for QuVa Pharma, Inc.

QuVa Pharma, Inc. does not have any Key Executives recorded.

QuVa Pharma, Inc. Key Developments

Endo International plc Obtains Preliminary Injunction Against Quva Pharma, Inc. Preventing Marketing and Release of Vasopressin Product

Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC (Par), have obtained a preliminary injunction preventing QuVa Pharma, Inc. (QuVa) from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict, the first and only vasopressin injection, USP, product approved by the U.S. Food and Drug Administration. The preliminary injunction, issued by the Hon. Brian R. Martinotti, U.S. District Judge, is effective through the conclusion of a trial, which has not yet been scheduled. In August 2017, Par filed a complaint against QuVa and several individual defendants in the U.S. District Court for the District of New Jersey (Case No. 17-6115) alleging, among other claims, the misappropriation of Par's trade secrets by the defendants in connection with QuVa's development of a bulk compounded vasopressin product.

QuVa Pharma, Inc. Announces New Equity and Debt Funding

QuVa Pharma, Inc. announced it has raised additional debt and equity funding of up to $40 million to support business growth initiatives. The funding includes $15 million from Bain Capital Private Equity and other existing shareholders, $20 million Term Loan from Silicon Valley Bank and a $5 million lease facility from Farnam Street Financial. With this additional capital infusion, total capital invested to date will approach $200 million.

QuVa Pharma Seeks Acquisitions

QuVa Pharma, Inc. is seeking acquisitions. Chris Gordon, Managing Director of Bain Capital Private Equity, LP said, "we are pleased to support the QuVa Pharma management team as they continue to acquire, build and operate quality-focused compounding facilities. We are encouraged by the strong market demand for their innovative, safety-oriented approach and will continue to commit significant resources in backing this industry-pioneering venture."

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 31, 2018
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact QuVa Pharma, Inc., please visit www.quvapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.